Clinical Research Directory
Browse clinical research sites, groups, and studies.
Open Label Safety/Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) in Patients With Cervical Dystonia
Sponsor: Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Summary
Open label study to evaluate the safety and immunogenicity of MYOBLOC (Botulinum Toxin Type B) in adult patients with a clinical diagnosis of Cervical Dystonia (CD).
Official title: An Open Label Safety and Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) Injectable Solution in Patients With Cervical Dystonia
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
502
Start Date
2001-06
Completion Date
2008-09
Last Updated
2026-05-11
Healthy Volunteers
No
Conditions
Interventions
Botulinum Toxin Type B
Eligible patients could receive injections of MYOBLOC once every 12 weeks. Total Dose could range from 5,000 Units up to 25,000 Units.